Medical technology company Stryker (NYSE: SYK) will be reporting results this Thursday afternoon. Here’s what investors should know.

Stryker beat analysts’ revenue expectations by 1.6% last quarter, reporting revenues of $6.02 billion, up 11.1% year on year. It was a strong quarter for the company, with an impressive beat of analysts’ organic revenue estimates and a decent beat of analysts’ revenue estimates.

Is Stryker a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting Stryker’s revenue to grow 9.7% year on year to $6.03 billion, slowing from the 11.9% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $3.13 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Stryker has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 2.1% on average.

Looking at Stryker’s peers in the medical devices & supplies - diversified segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Neogen’s revenues decreased 3.6% year on year, beating analysts’ expectations by 2.6%, and Boston Scientific reported revenues up 20.3%, topping estimates by 1.9%. Neogen traded up 3.7% following the results while Boston Scientific was also up 2.5%.

Read our full analysis of Neogen’s results here and Boston Scientific’s results here.

There has been positive sentiment among investors in the medical devices & supplies - diversified segment, with share prices up 6.1% on average over the last month. Stryker is up 1.6% during the same time and is heading into earnings with an average analyst price target of $429.37 (compared to the current share price of $375.76).

Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.